{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:21Z","timestamp":1772121201730,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.lungcan.2023.107286","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T21:06:38Z","timestamp":1688418398000},"page":"107286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer"],"prefix":"10.1016","volume":"182","author":[{"given":"H.C.","family":"Donker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cuppens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Froyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.M.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-J.","family":"Volders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.A.","family":"Lunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107286_b0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2023.107286_b0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","article-title":"Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer","volume":"35","author":"Sholl","year":"2022","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107286_b0015","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: A perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107286_b0020","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107286_b0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tig.2021.08.007","article-title":"Therapeutic and prognostic insights from the analysis of cancer mutational signatures","volume":"38","author":"Brady","year":"2022","journal-title":"Trends Genet."},{"issue":"6230","key":"10.1016\/j.lungcan.2023.107286_b0030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107286_b0035","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.lungcan.2023.107286_b0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2020.10.033","article-title":"Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC","volume":"23","author":"Chong","year":"2021","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Nature Cancer"},{"issue":"29","key":"10.1016\/j.lungcan.2023.107286_b0050","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-32499-3","article-title":"Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer","volume":"13","author":"Donker","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2023.107286_b0060","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","author":"Ravi","year":"2023","journal-title":"Nat. Genet."},{"issue":"7463","key":"10.1016\/j.lungcan.2023.107286_b0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer (vol 500, pg 415, 2013)","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107286_b0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2019.03.001","article-title":"A compendium of mutational signatures of environmental agents","volume":"177","author":"Kucab","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107286_b0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-020-00462-x","article-title":"Use of an integrated pan-cancer oncology enrichment next-generation sequencing assay to measure tumour mutational burden and detect clinically actionable variants","volume":"24","author":"Pestinger","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.lungcan.2023.107286_b0085","doi-asserted-by":"crossref","unstructured":"C. Zhao, et al., TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted Sequencing. bioRxiv, 2020: p. 2020.10.21.349100.","DOI":"10.1101\/2020.10.21.349100"},{"key":"10.1016\/j.lungcan.2023.107286_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels","author":"Endris","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107286_b0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jmoldx.2020.02.009","article-title":"Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes","volume":"22","author":"Kroeze","year":"2020","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01871-0","article-title":"Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden","volume":"22","author":"van den Heuvel","year":"2021","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107286_b0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2022.11.030","article-title":"Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC","volume":"18","author":"Ernst","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107286_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.05.019","article-title":"HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors","volume":"170","author":"Cuppens","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107286_b0115","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.2147\/OTT.S196638","article-title":"Assessment of tumor mutation burden calculation from gene panel sequencing data","volume":"12","author":"Xu","year":"2019","journal-title":"Oncotarget. Ther."},{"issue":"7781","key":"10.1016\/j.lungcan.2023.107286_b0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2023.107286_b0125","unstructured":"Illumina DRAGEN TruSight Oncology 500 Analysis Software v2.1 (Local), User Guide. 2022."},{"key":"10.1016\/j.lungcan.2023.107286_b0130","doi-asserted-by":"crossref","unstructured":"A.R. Quinlan, I.M. Hall, BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 26(6) (2010) 841-842.","DOI":"10.1093\/bioinformatics\/btq033"},{"key":"10.1016\/j.lungcan.2023.107286_b0135","doi-asserted-by":"crossref","unstructured":"X. Wang, J. Ren, Q. Zhao, Abstract 5004: Integrative quality control of cancer somatic mutations with CaMutQC. Cancer Res., 82(12_Supplement) (2022) 5004-5004.","DOI":"10.1158\/1538-7445.AM2022-5004"},{"key":"10.1016\/j.lungcan.2023.107286_b0140","doi-asserted-by":"crossref","unstructured":"S. Neph, et al., BEDOPS: high-performance genomic feature operations. Bioinformatics, 28(14) (2012) 1919-1920.","DOI":"10.1093\/bioinformatics\/bts277"},{"issue":"6755","key":"10.1016\/j.lungcan.2023.107286_b0145","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/44565","article-title":"Learning the parts of objects by non-negative matrix factorization","volume":"401","author":"Lee","year":"1999","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107286_b0150","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"Budczies","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107286_b0155","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ejhg.2011.28","article-title":"The GENCODE exome: sequencing the complete human exome","volume":"19","author":"Coffey","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0160","article-title":"The mutational signatures of formalin fixation on the human genome","volume":"13","author":"Guo","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107286_b0165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1101\/gr.226845.117","article-title":"Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers","volume":"28","author":"Meier","year":"2018","journal-title":"Genome Res."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107286_b0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1101\/gr.230219.117","article-title":"In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors","volume":"28","author":"Boot","year":"2018","journal-title":"Genome Res."},{"key":"10.1016\/j.lungcan.2023.107286_b0175","unstructured":"S., Nik-Zainal, et al., The genome as a record of environmental exposure. Mutagenesis, 30(6) (2015) 763-770."},{"issue":"15","key":"10.1016\/j.lungcan.2023.107286_b0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1700759114","article-title":"Mutational spectra of aflatoxin B 1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma","volume":"114","author":"Chawanthayatham","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107286_b0185","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jmoldx.2022.01.008","article-title":"Evaluation of the TruSight Oncology 500 assay for routine clinical testing of tumor mutational burden and clinical utility for predicting response to pembrolizumab","volume":"24","author":"Wei","year":"2022","journal-title":"J. Mol. Diagn."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107286_b0190","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","article-title":"Harmonization and standardization of panel-based tumor mutational burden measurement: Real-world results and recommendations of the quality in pathology study","volume":"15","author":"Stenzinger","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107286_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68394-4","article-title":"Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing","volume":"10","author":"Heydt","year":"2020","journal-title":"Sci. Rep."},{"issue":"7793","key":"10.1016\/j.lungcan.2023.107286_b0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:09Z","timestamp":1759237569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"alternative-id":["S0169500223008243"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107286","relation":{"has-preprint":[{"id-type":"doi","id":"10.31219\/osf.io\/gmb83","asserted-by":"object"}]},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107286"}}